Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis

作者：Sobral Leite Marcelo; Wesseling Jelle; Smit Vincent T H B M; Nevanlinna Heli; van Miltenburg Martine H; Sanders Joyce; Hofland Ingrid; Blows Fiona M; Coulson Penny; Patrycja Gazinska; Schellens Jan H M; Fagerholm Rainer; Heikkila Paivi; Aittomaki Kristiina; Blomqvist Carl; Provenzano Elena; Ali Hamid Raza; Figueroa Jonine; Sherman Mark; Lissowska Jolanta; Mannermaa Arto; Kataja Vesa; Kosma Veli Matti; Hartikainen Jaana M; Phillips Kelly Anne; Couch Fergus J

来源：BMC Medicine, 2015, 13(1): 156.

DOI：10.1186/s12916-015-0392-6

• Breast cancer
• Annexin A1
• BRCA1 and BRCA2 mutations

Background: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients.
Methods: Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model.
Results: The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P < 0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05-1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91-1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17-2.45).
Conclusions: ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.

• 出版日期2015-7-2